Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Nice close considering all the expectations of falling to .10!!!
WHAT EVER HAPPENED TO MISIU45?
I miss her posts. They were always interesting with news on Leronlimab.
Another baggie! How we looking after today’s SEC filing?
Damn, it’s almost painful embarrassing you fools. It’s too easy
FINALLY!!!! A post you will be correct on!
Well done, bud!
Laughing!
Two fools yodeling with each other!! You going to accept the results of the bet or renege like Tom?
I said it will hit $.10 by July 4!! You said it wouldn’t. If I’m wrong, I’ll never post again on this board? You took the offer! ‘Nise is already backpedaling.
What say you?? Once you decide, please re-read my prediction and compare the events to Jay-Jay’s pump call and ask yourself who was correct!
Bahahaha! $.09 here we come on way to Chapter 11
Hey Grip: thank heavens i do not make promises. I’ll be here when it hits ten cents and beyond.
Look at these complete morons on reddit!!!! "Several aspects of the SEC filing regarding CytoDyn's warrant exercise offer might hint at the possibility of upcoming positive news or strategic announcements, such as new partnerships or collaborations"
Lollllllllll what's next for these idiots?
"several aspects of the SEC filing regarding CytoDyn's bankruptcy might hint at the possibility of upcoming positive news or strategic announcements, such as new partnerships or collaborations"
Thanks Closet- sounds worse than I read originally.
The 13% vig is unbelievable. What do you suspect with the price action? I suspect it will hit around $.10 within the week but much depends on whether many longs accept the deal and exercise.
The company will be dumping them like hotcakes. This was the logical end result.
Always appreciate your input!
Grip - Per the math in the filing, each share is 7.9, which includes 1 warrant, another .2 shares and more than 13% cash to Paulson!
7.9 cents per unit!
Congrats Gilead! Impressive HIV results! Oh hi CYDY... Yeeeeahhh sorry
Tom- want to revisit this comically desperate gibberish?
Did you read the SEC filing today? If not, let me help you and the others that will be exiting this board this week or next!
Your boy, Jay Jay just sold your broke ass down the river! $.09 (NINE PENNIES) is the new offering price.
Thanks for playing along. Sure you wish you listened. You seem like a nice person but refuse to believe your lying eyes.
BTW- you think MissyMooMoo is pissed she can’t respond within in Hub jail!
Have a great weekend
New warrant terms issued today in SEC filing. Effective price is now 7.9 cents per share, plus company pays a 13% commission on the funds (plus even more warrants).
Grip's suggestion of 10 cents as a trading price may have been generous.
She tried to make it appear as if supporting the other dark morons who wrote that CytoDyn as a company was also being sued by the Feds.
I most certainly did not. I copied the title from the SEC's Enforcement page:
https://www.sec.gov/news/press-release/2022-232
Stop making shit up.
LOLOLOL
Market-moving information that was untrue?
Hmm, like “IT’S INFRASTRUCTURE WEEK” every other week, only to have nothing done?
Maybe it was Foxconn going to create thousands of jobs….oh wait!
Or maybe pumping up the steel and concrete industry to build a wall that Mexico would pay for!
Well-played!!!
The famous Janice wrote this "SEC Charges Former CEO of Biotech Company CytoDyn with Fraud, Insider Trading
Research Firm CEO Who Interacted with FDA on Company’s Behalf Also Charged"
She tried to make it appear as if supporting the other dark morons who wrote that CytoDyn as a company was also being sued by the Feds.
But should pigeons read and interpret plain English, they wouldn't post such misinformation to mislead investors. Is this action of their legal?
https://www.sec.gov/news/press-release/2022-221 Ouch!
Two House lawmakers asked SEC Chair Gary Gensler on April 9 for more information on how the Securities and Exchange Commission is monitoring the impact of investment-related misinformation on short-selling activity.
In their April 9 letter, first obtained by Politico, Reps. Bill Foster, D-Ill., and Blaine Luetkemeyer, R-Mo., who both serve on the House Financial Services Committee, raised concerns to Gensler about "assertions that some issuers have experienced falling stock prices due to market-moving information that was untrue.”
https://www.pionline.com/washington/house-lawmakers-flag-misinformations-impact-short-selling-sec
That’s cute! Not as cute as you losing your shirt on this but a good example why some come on this board to embarrass certain longs!
Welcome to a club you don’t want to be a member of! Hope you had a great weekend
Indeed the language in the SEC filings would have disappeared like the FDA warning on the website did after those issues were resolved. Ergo, the investigations are still ongoing. If they had been wrapped up in CYDY's favor you can bet Tanya or Jay Lala would have PR'd it ASAP.
These idiots don't understand that this investigation they've been "cooperating" with has been going on for over a year (is it two yet?). If there was nothing there they would have wrapped up ages ago. Idiot longs can't read the writing on the wall.
CYDY longs are the biggest group of idiots on the planet
Just Astonishing, As I was shutting my businesses down last friday, I posted a positive comment about a good day and a great weekend coming up, wishing for the 24/7 hate spewing trolls a break since the market would be closed for two days, they may be able to take a break and go outside and breath and enjoy, as opposed to allowing this company to live in their mind rent free 24/7 and control them. Unfortunately, when I checked back today, I noticed neg responses to my post late up into the night on friday, how miserable home life one must have nothing better to demand their attention on a friday night, so sad really. But the awesome CCR5 Blocker leronlimab with our Rock Star CEO Dr Jay are on the way to the promise land, don’t miss out! Sure hope this is not off topic, concerned for fellow message board members, best intentions always!
Not to beat this into the ground but moneycrew and since2012 were challenging justafacts that he had no facts that the company was charged. I think, when you posted, and stated “here is the documentation,” moneycrew assumed you were in justdafacts camp.
I agree you did not state it.
Not at all. He was claiming I'd said the company had been charged by the SEC.
I think moneycrew was asking, not claiming anything you said.
As a fiduciary, the company will be liable for shareholder lawsuits, which will come fast and furious.
You, along with others voted for him while discounting his past criminal behavior and stealing shares twice.
Look up fiduciary, read it very slow then google if a company can be held liable for monetary damages from an executive.
Nothing in the SEC filings indicates any settlement. Actually, the opposite is true.The filings are clear that the company is still cooperating and unable to assess the damage.
Have a good one
You didn’t- they make shit up! If you say it, it must be true
Nowhere. Where did I say it was?
where does it say the company was charged? Do you have the same selective reading issues as justnofacts?
yes, he still claims Cytodyn is under investigation because they have not announced that the supposed investigation is closed. Hahaha, too funny
bwahahahaha, what a joke. Time to give up the game, move on before Cytodyn really shows you who's boss. Anything else in the archives that would play into the your poorly attempted bashing game?
Got anything from 1973?
Here is the documentation:
SEC Charges Former CEO of Biotech Company CytoDyn with Fraud, Insider Trading
Research Firm CEO Who Interacted with FDA on Company’s Behalf Also Charged
https://www.sec.gov/news/press-release/2022-232
The complaint:
https://www.sec.gov/files/litigation/complaints/2022/comp-pr2022-232.pdf
“Uh yes, matters not what the board did except if they too sold shares at the same time. If they participated knowingly that has to be proved in another court setting.”
Wrong. Reference the 2 previous shareholder lawsuits CYDY settled, including one based on NP’s “unmitigated greed.” No difference this time around as NP is at the center of the current shareholder lawsuits.
Company not charged with anything, are you saying they are, somebody already went done that rabbit hole FF
Uh yes, matters not what the board did except if they too sold shares at the same time. If they participated knowingly that has to be proved in another court setting. They were mpt included after a long investigation. If any were part of it, let them fall as well. But the entity as a corporation was defrauded not the other way around.
But talk about defrauding... all the children of the world. Ouuucchh. The hammer is dropping. How could our competition supported by pigeons been so willingly destructive to the families? Look at this manipulation of data. AND they got approval after their EUA that should have been withdrawn were the FDA CDC NIH DoD and a few others doing the job as codified. https://live.childrenshealthdefense.org/chd-tv/?utm_id=chdtvemail
Leronlimab, a safe drug after many trials was denied by FDA insiders per emails and conversations coming out from FOIA and discovery. What will the judge allow in the Pour Iranians trial... a grander conspiracy than pigeons can imagine? Let the bird chit fall where it may. Clean out the corruption where ever it is found. Covering it up and denying it's existence is participating in the corruption that has killed millions of lives and by killing a drug that could have saved millions.
Go Leronlimab, Go Dr. Jay, $CYDY$ 2024 on this American Juneteenth Holiday.
"alleges" got NP and KK in handcuffs too...think about it with that little pea sized foreign brain.
A link directly from the the US Justice Department dated December 20, 2022 is "old as dirt"? At least try to be realistic and not be skewed by a pathetic and dumb investment decision.
CYDY announce the DOJ and SEC investigations have concluded? NOPE!
In my humble opinion the co may be charged along with the the possibility of Paulson and a few other assorted individuals and pumpers.
Hey morrrrrrans how's that long thesis treating ya
" alleges "...and your link is as old as dirt, give it another try.
I don’t know closet, the DOJ is not looking at CytoDyn and Nada as one unit.
LOL, really??? Looks like one unit to me---
“I don’t know closet, the DOJ is not looking at CytoDyn and Nada as one unit.”
We’re talking criminal vs civil cases. NP is the one who is alleged to have committed the crimes while serving as CEO. From a civil standpoint, CYDY misled investors under the leadership of NP and the BOD. Note that at this point the civil cases are still pending and haven’t been dismissed which indicates CYDY may be liable for NP’s actions. This wouldn’t be the first time a company pays a settlement to shareholder due to fraud by officers within the company.
“G…Heck,, they’re not even prosecuting other executives when Nada was on the team trying to advance Leronlimab,, leronjimab…G,, that video on YouTube was hilarious…”
That’s because they’re supporting the federal case or I assume they are.
“Another thing to note is…they’re not prosecuting Scott Kelly who was arguably the boss of Nada…”
Nobody was the boss of Nada. He fired anyone who questioned him and hired everyone who wouldn’t. Reference settled shareholder lawsuits for facts supporting that statement.
“However,, if Nada won,, and it showed moving of the goal posts for indications including,, but not limited to BLA and EUA process…”
The available court documents still fail to clear NP of the fraud charges involving the BLA (or that’s my opinion of what’s been filed). The making of the goal posts (justified), bias (justified), etc., was all a result of NP’s poor interactions with the FDA dating back ten years. Can’t blame them.
I don’t know closet, the DOJ is not looking at CytoDyn and Nada as one unit.
G…Heck,, they’re not even prosecuting other executives when Nada was on the team trying to advance Leronlimab,, leronjimab…G,, that video on YouTube was hilarious…
Another thing to note is…they’re not prosecuting Scott Kelly who was arguably the boss of Nada…
However,, if Nada won,, and it showed moving of the goal posts for indications including,, but not limited to BLA and EUA process…
Than one could figure THAT would bold well for CytoDyn…and its shareholders…
And that’s one reason to be bullish imo. Very very bullish for CytoDyn !!
“Nader and Iranian co-hart most likely to be found defrauding the company. So damages in favor of CytoDyn may well happen.”
Um, no. Both were CEOs of the company and defrauded investors. NP will
not be paying CYDY back as the BOD kept voting him in. CYDY may have to settle lawsuits due to NP’s fraud.
Both may well bring in lots of moolah. AmarX will settle. Could see a price over the $100 million the company is seeking.
Nader and Iranian co-hart most likely to be found defrauding the company. So damages in favor of CytoDyn may well happen.
KazaamePoor or whatever his name is may well be sued to by his own company NSI. Remains to be seen as these days the
courts have gone totally haywire. Is it justice or justus? All depends on what dialect one uses. In any case, we are the party
injured. Exactly who all the known actors would be, is still up for grabs. One thing for sure, the boys are trying to separate themselves....
because, because two or more in cahoots is a RICO conspiracy. Which is why we have seen them trying to separate in testimony
and depositions. That in my opinion is a tough sell. They sold too many shares and that was the easy sell coming back to haunt. Kind of like being caught short!
Truth has a strange way of surfacing. In any case, the court and any behind the scene Ex Parte will be what probably bangs the gavel.
So y'all, be good, have a safe Juneteenth. Out of here. $CYDY$ 2024
Amarex case: could bring in money for the company.
Nader Case: could cost the company money if he’s found guilty.
Is the Nadar case / Amarex case actually possibly going to result in cash for CytoDyn? Might be a way to fund the trials at this point funding options seem grim.
Eli Lilly needs leronlimab to study in tandem with donanemab. The Aria problem could be solved. So what company wants to collaborate with CytoDyn in the area of Alzheimer's? https://edition.cnn.com/2024/06/10/health/fda-committee-recommends-eli-lillys-alzheimers-drug-donanemab/index.html
From May update Letter To Shareholders:
"Research and development partnership opportunities are important to the Company as we search for cost-effective ways to further build out our product development portfolio. We have identified several such opportunities that we believe are intriguing, and anticipate finalizing agreements with these partners in the very near future. Such potential partnerships include an investigator-initiated pilot study of leronlimab in patients with Alzheimer’s Disease, and a project that will evaluate the use of leronlimab in patients living with HIV who are undergoing stem cell transplantation in a proof of cure study. Following lifting of the clinical hold, we have observed a significant increase in third parties that are interested in partnering with the Company. We will continue to review opportunities as they arise, given the potential for significant value return at little or no cost to the Company.
Finally, as promised, CytoDyn (CYDY.NaE) has submitted several leronlimab manuscripts for peer review and is in the process of completing final drafts of several others. The clinical endpoint data from the Long COVID trial (CD 15) was recently published in the Journal of Infection. All publications will be available on the Company’s website soon after publication.
I believe the Company is building for success and has made significant strides toward initiating a number of key pre-clinical and clinical leronlimab trials. I am also pleased to share that things are progressing well as to the development of a longer-acting therapeutic with our partner who utilizes its proprietary artificial intelligence platform.
As shareholders, you are the lifeblood of the Company and we remain committed to acting in your best interests. Your questions and feedback are always appreciated. Included herewith is a copy of the May 2024 “Frequently Asked Questions” supplement. This FAQ supplement is something that is also posted on the Company’s website and updated from time to time. You are always welcome to submit questions to the Company’s IR email account: ir@cytodyn.com. "
Ask away pigeons. Get ready to fly!! $$CYDY$$ 2024 I feel something is soon to be released. Wait for it. Don't cover yet... feel the full brunt. Enjoy.
Hey Nisi! You’ve gone quiet! Hope you’re ok!
Touched in the $.12’s this morning and you were chirping about reasons why the call was had and there are things people aren’t privy to.
So with this inside info, should we be buying? Would love to know your thoughts or if you’ve finally seen the reality of this scam?
Have a great week
I would attract real investors. Doubt hedge fund guys are buying .13/share stock but what do I know.
A big shout out for Dr. Jay and the reconstructed team and advisors. What will this new AI collaboration reveal? What will Sidley reveal? What will Dr. Jay reveal? What will the AmarX conspiracy with Nader reveal? One thing for sure. An open mind creates progress. Sometimes two steps back makes for a giant leap forward. Watch for it.
I know how difficult it is for some folks even scientist who only want to validate their data. However, this is not real science. An investigator, like scientists are supposed to be... maintain an open mind to new data and at least say to themselves, let's check this out. This is how things are done in the real world of science in the real world of seeking the truth or in the real world of creativity where new improvements upon old ideas lead to great breakthroughs and products.
What if... ok, let's try it this way and see what happens. This is the nature of man and especially for the few who make generational breakthroughs. Those who only want to acknowledge their own work or of others with similar data/opinions suffer from a confirmation bias that slows progress. So this is exactly the opposite of these types who want to be known as "progressives". They are exactly the opposite of what they portend. Then there are those without any truth seeking merit because the ego blocks the inquisitive nature they were blessed with at birth.
Tanzania and few other countries objected to using the "vaccines". It seems surprising to some that these countries fared way better than those who choose the pricks. Of course, they were tired of being guinea pigs for Big Pharma experiments. So CytoDyn should consider studies in these countries even Ukraine or Russia!! Why not?
Tanzania, Africa
COVID
Since Aug.12, 2021 there were 604 deaths in the country.
As of May, 26, 2024 a grand total of 846 cumulative deaths.
The country had half the population with at least one dose.
As of May 26, 2024 a total of 43,226 confirmed cases.
Estimated cumulative excess deaths per 100,000 people during
COVID-19, Jun 10, 2024
USA=430
Tanzania=272
More is better? Any is better? Choose your poison.
Happy Father’s Day Kgro!
Hope you have a maxed out day!
Followers
|
813
|
Posters
|
|
Posts (Today)
|
0
|
Posts (Total)
|
233578
|
Created
|
11/18/05
|
Type
|
Free
|
Moderators janice shell kgromax |
DISCLAIMER:
Securities and Exchange Commission and Department of Justice Investigations
The Company has received subpoenas from the United States Securities and Exchange Commission requesting documents and information concerning, among other matters, leronlimab, the Company’s public statements regarding the use of leronlimab as a potential treatment for COVID-19 and related communications with the FDA, investors, and others, and trading in the securities of CytoDyn. The SEC has informed the Company that this inquiry should not be construed as an indication that any violations of law have occurred or that the SEC has any negative opinion of any person, entity or securities trading activity.
In addition, the Company and certain of its executives have received subpoenas in connection with an investigation being conducted by the United States Department of Justice. The subpoenas seek testimony and/or records concerning, among other matters, leronlimab, the Company’s public statements regarding the use of leronlimab as a potential treatment for COVID-19 and related communications with the FDA, investors, and others, and trading in the securities of CytoDyn.
Securities and Exchange Commission and Department of Justice Investigations
The Company has received subpoenas from the United States Securities and Exchange Commission (“SEC”) and the United States Department of Justice (“DOJ”) requesting documents and information concerning, among other matters, leronlimab, the Company’s public statements regarding the use of leronlimab as a potential treatment for COVID-19, HIV, and triple-negative breast cancer, related communications with the FDA, investors, and others, litigation involving former employees, the Company’s retention of investor relations consultants, and trading in the Company’s securities. Certain Company executives have received subpoenas concerning similar issues and may be interviewed by the DOJ or SEC in the future. The SEC informed the Company that its inquiry should not be construed as an indication that any violations of law have occurred or that the SEC has any negative opinion of any person, entity or security.
The Company is cooperating fully with these non-public, fact-finding investigations, and as of the date of this filing, the Company is unable to predict the ultimate outcome and cannot reasonably estimate the potential possible loss or range of loss, if any.
VANCOUVER, Washington, March 30, 2022 (GLOBE NEWSWIRE) -- CytoDyn Inc. (OTCQB: CYDY) ("CytoDyn" or the "Company"), a late-stage biotechnology company developing leronlimab, a CCR5 antagonist with the potential for multiple therapeutic indications, announced that the U.S. Food and Drug Administration (FDA) has placed a partial clinical hold on its HIV program and a full clinical hold on its COVID-19 program in the United States. Further, the Company elected to pause its Brazil COVID-19 trials pending results from its previously scheduled data safety monitoring committee meeting and is in the process of reevaluating the timing of its HIV BLA resubmission.
The Company was not enrolling any new patients in the trials placed on hold in the United States. The partial clinical hold on the HIV program impacts patients currently enrolled in extension trials. These patients will be transitioned to other available therapeutics and no clinical studies can be initiated or resumed until the partial clinical hold is resolved. CytoDyn intends to work closely with the FDA to resolve the partial clinical hold as soon as possible. Under the full clinical hold on the COVID-19 program, no new clinical studies may be initiated until the clinical hold is resolved. The Company is not currently conducting any COVID-19 trials in the United States, as it is evaluating the most optimal programs on which to focus its resources and attention.
“CytoDyn is committed to FDA compliance,” said Scott A. Kelly, M.D., Chief Medical Officer of CytoDyn. “We are evaluating our clinical programs and are working to resolve the issues underlying the clinical holds as soon as possible in close communication with the FDA. We will provide an update when we have additional information.”
Up to 205,652,848 Shares of Common Stock
This prospectus supplement updates, amends and supplements the prospectus dated October 11, 2023, relating to our Registration Statement on Form S-1 (Registration No. 333-272815) (as supplemented or amended from time to time, the “Prospectus”). Capitalized terms used in this prospectus supplement and not otherwise defined herein have the meanings specified in the Prospectus.
This prospectus supplement is being filed to supplement the Prospectus with the following information:
The information in this prospectus supplement includes forward-looking statements relating to, among other things, future clinical trials and our business strategy. The reader is cautioned not to rely on these statements, which are based on our current expectations. Please see below for additional information about risks involving our securities.
This prospectus supplement is not complete without the Prospectus. This prospectus supplement should be read in conjunction with the Prospectus, which is to be delivered with this prospectus supplement, and is qualified by reference thereto, except to the extent that the information in this prospectus supplement updates or supersedes the information contained in the Prospectus. Please keep this prospectus supplement with your Prospectus for future reference. The Prospectus, together with this prospectus supplement, relates to the resale of up to 74,903,789 shares of our common stock, par value $0.001 per share (the “common stock”), and 130,749,059 shares of our common stock underlying certain warrants (collectively, the “Shares”), by the selling stockholders identified in the Prospectus under “Selling Stockholders”.
Our common stock is quoted on the OTCQB of OTC Markets Group, Inc. under the symbol “CYDY.” On February 29, 2024 the closing price of our common stock was $0.2575 per share.
Investing in our securities involves risk. You should carefully consider the risks that we have described under the section captioned “Risk Factors” in the Prospectus on page 8 and in Part II, Item 1A of the 2024 Second Quarter 10-Q before buying our securities.
Neither the Securities and Exchange Commission nor any state securities commission has approved or disapproved of these securities or determined if the Prospectus or this prospectus supplement is truthful or complete. Any representation to the contrary is a criminal offense.
The date of this prospectus supplement is March 1, 2024.
November 3, 2023
November 2023 Letter to Shareholders
Dear Shareholders,
We write to provide an update on CytoDyn Inc. (“CytoDyn” or “Company”), and to thank you for your continued support of the Company.
Throughout our history, CytoDyn has made great strides in developing leronlimab from a single indication molecule into a platform molecule with the potential for multiple therapeutic indications. Through CytoDyn’s investment in clinical trials, we have generated valuable data demonstrating how leronlimab might be used in HIV, oncology, metabolic dysfunction-associated steatohepatitis (“MASH” formerly “NASH”), and metabolic dysfunction-associated steatotic liver disease (“MASLD”). We have also successfully transferred our manufacturing technology allowing us to manufacture leronlimab at scale in preparation for clinical trials and potential FDA approval.
Fiscal year 2023 proved to be a very difficult year for CytoDyn. We had planned to be off clinical hold and back to conducting clinical trials by now. Unfortunately, to date, we have been delayed in our efforts to satisfy the FDA with our clinical hold submission(s). We have embarked on a more comprehensive effort to resolve the FDA’s lingering questions. These efforts include the Company’s hosting of a number of advisory board meetings with key opinion leaders (KOLs). Adding to our delay was the unanticipated medical leave taken by our then President, Dr. Arman creating additional delays in our subsequent resubmission.
However, these unforeseen circumstances provided the time needed to help us gain new insights and understanding of leronlimab in the current HIV treatment environment. Further, we were able to receive and incorporate the perspectives of some of the top HIV KOLs worldwide as to how they believe leronlimab can play a significant role in helping HIV patients, notwithstanding other therapeutic options currently available to patients. As part of this process, the Company engaged various new clinical, regulatory, and medical consultants and advisors with relevant experience and expertise that we believe will continue to benefit the Company for years to come.
The Company has taken necessary actions to position us for near-term and long-term success. During the last fiscal year, the Company implemented significant reductions to its workforce, cash burn rate, and operating expenses, in order to conserve our resources and devote them to critical corporate priorities. In addition to our work in HIV, we have worked with top experts to develop a MASH clinical trial protocol and identify potential MASH pre-clinical combination therapy trial concepts, which trials we believe could be attractive to a partner and position the Company for a greater chance of success within the MASH space. We also began development of a longer-acting therapeutic with a partner who has a very strong and reputable artificial intelligence (“AI”) platform, which we believe may provide significant increases in shareholder value in the years to come. We also believe that the Company is positioned for success in the Amarex litigation. We fully funded Sidley Austin LLP – the preeminent law firm representing the Company in this matter, filed a more-detailed statement of claim, and scheduled a final hearing date (August 12, 2024) in the arbitration.
We understand that CytoDyn’s recent challenges may have tested your confidence. We want to assure you that we remain dedicated to developing important therapeutics that can make a difference in
patients' lives, and at the same time provide value for our shareholders. Again, we are grateful for your ongoing support and trust.
We will continue our efforts to prioritize and execute on goals that will enhance value for all shareholders. Our efforts are focused on successfully completing the resolution of the FDA’s partial clinical hold – having recently made a submission that we hope will be successful – and strengthening our leadership team. Additionally, the Company will be evaluating the various potential indications for leronlimab to maximize the effective and efficient use of our resources. We have always believed leronlimab holds great promise, and we are determined to explore all avenues by which patients and medical practitioners can benefit from its use. We believe that with the improvements we have made and continue to pursue, our company is positioned for long-term success.
We deeply value your investment in CytoDyn and are committed to acting in your best interests. We look forward to continuing to communicate as additional developments occur. We realize the updates above may not answer all the questions you have. We therefore include a November 2023 “Frequently Asked Questions” supplement with this letter. This FAQ supplement is something we intend to update from time to time and it will be posted on the Company’s website in the near future.
Finally, in advance of our upcoming Annual Meeting on November 9, 2023, we want to remind you to submit your votes, if you have not already done so. If you were a shareholder as of September 11, 2023, you are considered a shareholder of record. Notably, the Company has asked for the shareholders’ approval to amend the Company’s Certificate of Incorporation to increase the total number of authorized shares of common stock. This increased share allowance is critical to the ongoing viability of the Company, and we therefore encourage everyone to vote if you have not already done so. If you have any questions or require any assistance in voting your shares, please call the Company’s proxy solicitor, Alliance Advisors LLC, at (833) 814-9456.
Sincerely,
Tanya Durkee Urbach
Board Chair
Note Regarding Forward-Looking Statements
This letter and the accompanying Frequently Asked Questions supplement contain forward-looking statements relating to, among other things, future operating and financial performance, product development, market position and business strategy. The reader is cautioned not to rely on these statements, which are based on current expectations of future events. For important information about these statements and/or our Company, including the risks, uncertainties and other factors that could cause actual results to vary materially from the assumptions, expectations and projections expressed in any forward-looking statements, the reader should review the Annual Report on Form 10-K for the fiscal year ended May 31, 2023, including in the sections captioned “Forward Looking Statements” and “Item 1A. Risk Factors”, as later supplemented by our Form 10-Q for the quarter ended August 31, 2023, in the section captioned “Item 1A. Risk Factors”. CytoDyn Inc. does not undertake to update any forward-looking statement as a result of new information or future events or developments.
Volume | |
Day Range: | |
Bid Price | |
Ask Price | |
Last Trade Time: |